Based on the strength of data from randomized trials and real-world clinical studies, transcatheter aortic valve replacement (TAVR) has become a popular and effective alternative to surgical valve replacement in patients with symptomatic aortic stenosis. The ACURATE neo™ (Boston Scientific, Marlborough, MA, USA) valve system has been commercially available for transfemoral TAVR in Europe since 2014. ACURATE neo2™ is an evolution of the neo design and was declared CE marked by the manufacturer in 2020. The neo and neo2 valves have been studied in high-risk patients, and the currently active randomized trial for neo2 will include over 1,500 patients of all risk categories in the USA. The goal of this review is to help inform the TAVR community about the ACURATE valve.

Original languageEnglish (US)
Pages (from-to)37-41
Number of pages5
JournalHeart International
Issue number1
StatePublished - 2021


  • ACURATE neo valve system
  • Symptomatic aortic stenosis
  • Transcatheter aortic valve replacement (TAVR)

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'The acurate neo™ and neo2™ valve systems'. Together they form a unique fingerprint.

Cite this